What Rituxan treats.
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
- Pemphigus vulgaris
The mechanism.
Rituxan (rituximab) is a monoclonal antibody that targets and depletes CD20-positive B cells — immune cells that contribute to inflammation and autoimmune attack. By temporarily reducing B-cell activity, Rituxan helps quiet overactive immune responses driving disease.
Your Rituxan infusion experience.
First Rituxan infusions are given slowly — often 4 to 6 hours — with pre-medications (acetaminophen, antihistamine, and steroid) to reduce infusion reactions. Subsequent infusions are typically faster as your body adjusts. Treatment is given as two infusions two weeks apart, then repeated every 6 months or as your physician directs.
Insurance & out-of-pocket cost.
Rituxan is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.